CLAIRE YERXA: Open Payments
NPI 1700567617 · QUINCY, MA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,257 in 47 payments from 17 companies in 2025. Trend: 2023 $0 · 2024 $154 · 2025 $1,257
Food & beverage: $1,165Education: $92
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 9 | $240 |
| Regeneron Healthcare Solutions, Inc. | 7 | $232 |
| Grifols USA, LLC | 5 | $104 |
| Genentech USA, Inc. | 4 | $98 |
| GENZYME CORPORATION | 3 | $95 |
| BioCryst US Sales Co., LLC | 3 | $83 |
| Pharming Healthcare, Inc. | 3 | $78 |
| Novartis Pharmaceuticals Corporation | 3 | $78 |
| Lilly USA, LLC | 2 | $53 |
| CSL Behring | 1 | $34 |
Products named: DUPIXENT, FASENRA, Xolair, ORLADEYO, RUCONEST, TEZSPIRE, Prolastin-C Liquid, EBGLYSS.
Industry payments across MA — which companies pay providers there.
